...
首页> 外文期刊>BMC Structural Biology >The structure of Mycobacteria 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase, an essential enzyme, provides a platform for drug discovery
【24h】

The structure of Mycobacteria 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase, an essential enzyme, provides a platform for drug discovery

机译:分枝杆菌2C-甲基-D-赤藓糖醇-2,4-环二磷酸合酶的结构,一种必不可少的酶,为药物发现提供了平台

获取原文
           

摘要

Background The prevalence of tuberculosis, the prolonged and expensive treatment that this disease requires and an increase in drug resistance indicate an urgent need for new treatments. The 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid precursor biosynthesis is an attractive chemotherapeutic target because it occurs in many pathogens, including Mycobacterium tuberculosis, and is absent from humans. To underpin future drug development it is important to assess which enzymes in this biosynthetic pathway are essential in the actual pathogens and to characterize them. Results The fifth enzyme of this pathway, encoded by ispF, is 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (IspF). A two-step recombination strategy was used to construct ispF deletion mutants in M. tuberculosis but only wild-type double crossover strains were isolated. The chromosomal copy could be deleted when a second functional copy was provided on an integrating plasmid, demonstrating that ispF is an essential gene under the conditions tested thereby confirming its potential as a drug target. We attempted structure determination of the M. tuberculosis enzyme (MtIspF), but failed to obtain crystals. We instead analyzed the orthologue M. smegmatis IspF (MsIspF), sharing 73% amino acid sequence identity, at 2.2 ? resolution. The high level of sequence conservation is particularly pronounced in and around the active site. MsIspF is a trimer with a hydrophobic cavity at its center that contains density consistent with diphosphate-containing isoprenoids. The active site, created by two subunits, comprises a rigid CDP-Zn2+ binding pocket with a flexible loop to position the 2C-methyl-D-erythritol moiety of substrate. Sequence-structure comparisons indicate that the active site and interactions with ligands are highly conserved. Conclusion Our study genetically validates MtIspF as a therapeutic target and provides a model system for structure-based ligand design.
机译:背景技术结核病的流行,该疾病需要的长期昂贵的治疗以及耐药性的提高表明迫切需要新的治疗方法。类异戊二烯前体生物合成的1-脱氧-D-木酮糖5-磷酸途径是有吸引力的化学治疗靶标,因为它存在于许多病原体中,包括结核分枝杆菌,并且在人类中不存在。为了支持未来的药物开发,重要的是评估该生物合成途径中的哪些酶在实际病原体中必不可少并进行表征。结果该途径的第五种酶由ispF编码,是2C-甲基-D-赤藓糖醇-2,4-环二磷酸合酶(IspF)。使用了两步重组策略来构建结核分枝杆菌中的ispF缺失突变体,但仅分离了野生型双交换菌株。当在整合质粒上提供第二个功能拷贝时,可以删除染色体拷贝,这表明在测试条件下ispF是必需基因,从而确认了其作为药物靶标的潜力。我们尝试确定结核分枝杆菌酶(MtIspF)的结构,但未能获得晶体。相反,我们分析了直向同源的耻垢分枝杆菌IspF(MsIspF),在73?处共有73%的氨基酸序列同一性。解析度。高水平的序列保守性在活性位点内和周围特别明显。 MsIspF是三聚体,在其中心具有疏水腔,其密度与含二磷酸的类异戊二烯一致。由两个亚基形成的活性位点包括一个带有柔性环的刚性CDP-Zn 2+ 结合袋,用于定位底物的2C-甲基-D-赤藓糖醇部分。序列结构比较表明,活性位点和与配体的相互作用是高度保守的。结论我们的研究从基因上验证了MtIspF作为治疗靶点,并为基于结构的配体设计提供了模型系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号